Literature DB >> 8695160

Radiosensitivity of mesothelioma cell lines.

A M Häkkinen1, A Laasonen, K Linnainmaa, K Mattson, S Pyrhönen.   

Abstract

The present study was carried out in order to examine the radiosensitivity of malignant pleural mesothelioma cell lines. Cell kinetics, radiation-induced delay of the cell cycle and DNA ploidy of the cell lines were also determined. For comparison an HeLa and a human foetal fibroblast cell line were simultaneously explored. Six previously cytogenetically and histologically characterized mesothelioma tumor cell lines were applied. A rapid tiazolyl blue microtiter (MTT) assay was used to analyze radiosensitivity and cell kinetics and DNA ploidy of the cultured cells were determined by flow cytometry. The survival fraction after a dose of 2 Gy (SF2), parameters alpha and beta of the linear quadratic model (LQ-model) and mean inactivation dose (D(MID)) were also estimated. The DNA index of four cell lines equaled 1.0 and two cell lines equaled 1.5 and 1.6. Different mesothelioma cell lines showed a great variation in radiosensitivity. Mean survival fraction after a radiation dose of 2 Gy (SF2) was 0.60 and ranged from 0.36 to 0.81 and mean alpha value was 0.26 (range 0.48 - 0.083). The SF2 of the most sensitive diploid mesothelioma cell line was 0.36: less than that of the foetal fibroblast cell line (0.49). The survival fractions (0.81 and 0.74) of the two most resistant cell lines, which also were aneuploid, were equal to that of the HeLa cell line (0.78). The alpha/beta ratios of the most sensitive cell lines were almost an order of magnitude greater than those of the two most resistant cell lines. Radiation-induced delay of the most resistant aneuploid cell line was similar to that of HeLa cells but in the most sensitive (diploid cells) there was practically no entry into the G1 phase following the 2 Gy radiation dose during 36 h.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695160     DOI: 10.3109/02841869609109921

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  7 in total

Review 1.  Lung cancer * 8: Management of malignant mesothelioma.

Authors:  C Parker; E Neville
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

2.  PET-guided dose escalation tomotherapy in malignant pleural mesothelioma.

Authors:  Andrei Fodor; Claudio Fiorino; Italo Dell'Oca; Sara Broggi; Marcella Pasetti; Giovanni Mauro Cattaneo; Luigi Gianolli; Riccardo Calandrino; Nadia Gisella Di Muzio
Journal:  Strahlenther Onkol       Date:  2011-10-28       Impact factor: 3.621

Review 3.  Proton beam therapy for malignant pleural mesothelioma.

Authors:  Shahed N Badiyan; Jason K Molitoris; Mingyao Zhu; Erica Glass; Tejan Diwanji; Charles B Simone
Journal:  Transl Lung Cancer Res       Date:  2018-04

4.  The dosimetric enhancement of GRID profiles using an external collimator in pencil beam scanning proton therapy.

Authors:  Blake R Smith; Nicholas P Nelson; Theodore J Geoghegan; Kaustubh A Patwardhan; Patrick M Hill; Jen Yu; Alonso N Gutiérrez; Bryan G Allen; Daniel E Hyer
Journal:  Med Phys       Date:  2022-02-21       Impact factor: 4.071

5.  A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.

Authors:  Stephanie R Rice; Yun R Li; Theresa M Busch; Michele M Kim; Sally McNulty; Andrea Dimofte; Timothy C Zhu; Keith A Cengel; Charles B Simone
Journal:  Photochem Photobiol       Date:  2018-12-28       Impact factor: 3.421

Review 6.  Radiotherapy for malignant pleural mesothelioma.

Authors:  E Chapman; E G Berenstein; M Diéguez; Z Ortiz
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

7.  Stereotactic Body Radiation Therapy (SBRT) as Salvage Therapy for Oligorecurrent Pleural Mesothelioma After Multi-Modality Therapy.

Authors:  Christina Schröder; Isabelle Opitz; Matthias Guckenberger; Rolf Stahel; Walter Weder; Robert Förster; Nicolaus Andratschke; Olivia Lauk
Journal:  Front Oncol       Date:  2019-09-26       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.